Antiviral applications of RNAi for coronavirus

Expert Opinion on Investigational Drugs

Volumn 15, Issue 2, 2006, Pages 89-97

  Wu, Chang Jer ^a   Chan, Yi Lin ^b  

^a NATIONAL TAIWAN OCEAN UNIVERSITY   (Taiwan)

^b NATIONAL DEFENSE UNIVERSITY   (Taiwan)

Author keywords

Antiviral agent; Coronavirus; Severe acute respiratory syndrome; Short interfering RNAs

Indexed keywords

ANTIVIRUS AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; MICROSOMAL AMINOPEPTIDASE; RNA POLYMERASE; SMALL INTERFERING RNA; VIRUS ANTIGEN; VIRUS RNA;

ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; DRUG MECHANISM; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC CODE; GENETIC TRANSCRIPTION; INFECTION CONTROL; INFLUENZA; NONHUMAN; OPEN READING FRAME; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RNA INTERFERENCE; RNA SEQUENCE; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; TAXONOMY; VIRUS PARTICLE; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CORONAVIRUS; CORONAVIRUS INFECTIONS; HUMANS; RNA INTERFERENCE;

EID: 32844457215     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.2.89     Document Type: Review

References (93)

1. LAI MMC, HOLMES KV: Coronaviridae: the viruses and their replication. In: Fields' Virology. Knipe D, Howley P (Eds), Lippincott Williams & Wilkins, Philadelphia, USA (2001):1163-1185.
2. HOLMES KV: Coronaviruses. In: Fields' Virology. Knipe D, Howley P (Eds), Lippincott Williams & Wilkins, Philadelphia, Pennsylvania, USA (2001):1187-1203.
3. DROSTEN C, GUNTHER S, PREISER W et al.: Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. (2003) 348(20):1967-1976.
4. KSIAZEK TG, ERDMAN D, GOLDSMITH CS et al.: A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. (2003) 348(20):1953-1966.
5. FOUCHIER RA, KUIKEN T, SCHUTTEN M et al.: Aetiology: Koch's postulates fulfilled for SARS virus. Nature (2003) 423(6937):240.
6. PEIRIS JS, LAI ST, POON LL et al.: Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet (2003) 361(9366):1319-1325.
7. ROTA PA, OBERSTE MS, MONROE SS et al.: Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science (2003) 300(5624):1394-1399.
8. STADLER K, MASIGNAN V, EICKMANN M et al.: SARS - beginning to understand a new virus. Nat. Rev. Microbiol. (2003) 1(3):209-218.
9. PEIRIS JS, GUAN Y, YUEN KY: Severe acute respiratory syndrome. Nat. Med. (2004) 10(12):88-97.
10. FUJII T, NAKAMURA T, IWAMOTO A: Current concepts in SARS treatment. J. Infect. Chemother. (2004) 10(1):1-7.
11. HUI DS, WONG GW: Advancements in the battle against severe acute respiratory syndrome. Expert Opin. Pharmacother. (2004) 5(8):1687-1693.
12. DE CLERCQ E: Antivirals and antiviral strategies. Nat. Rev. Microbiol. (2004) 2(9):704-20.
13. MARSHALL E, ENSERINK M: Medicine. Caution urged on SARS vaccines. Science (2004) 303(5660):944-946.
14. CINATL J Jr, MICHAELIS M, HOEVER G, PREISER W, DOERR HW: Development of antiviral therapy for severe acute respiratory syndrome. Antiviral Res. (2005) 66(2-3):81-97.
15. WEGE H, SIDDELL S, TER MEULEN V: The biology and pathogenesis of coronaviruses. Curr. Top. Microbiol. Immunol. (1982) 99:165-200.
16. MARRA MA, JONES SJ, ASTELL CR et al.: The genome sequence of the SARS-associated coronavirus. Science (2003) 300(5624):1399-1404.
17. LAI MMC: SARS virus: the beginning of the unraveling of a new coronavirus. J. Biomed. Sci. (2003) 10(6):664-675.
18. LAI MMC, CAVANAGH D: The molecular biology of coronaviruses. In: Advanced Virus Research, Maramorosch K, Murphy FA, Shatkin A (Eds), New York Academic Press, New York, USA (1997) 48:1-100.
19. LAI MMC, PATTON CD, BARIC RS, STOHLMAN SA: Presence of leader sequences in the mRNA of mouse hepatitis virus. J. Virol (1983) 46(3):1027-1033.
20. SPAAN W, CAVANAGH D, HORZINEK MC: Coronaviruses: structure and genome expression. J. Gen. Virol. (1988) 69(12):2939-2952.
21. GORBALENYA AE, KOONIN EV, DONCHENKO AP, BLINOV VM: Coronavirus genome: Prediction of putative functional domains in the nonstructural polyprotein by comparative amino acid sequence analysis. Nucleic Acids Res. (1989) 17(12):4847-4861.
22. LEE HJ, SHIEH CK, GORBALENYA AE et al.: The complete sequence (22 kilobases) of murine coronavirus gene 1 encoding the putative proteases and RNA polymerase. Virology (1991) 180(2):567-582.
23. THIEL V, HEROLD J, SCHELLE B, SIDDELL SG: Viral replicase gene products suffice for coronavirus discontinuous transcription. J Virol. (2001) 75(14):6676-6681.
24. THIEL V, IVANOV KA, PUTICS AT et al.: Mechanisms and enzymes involved in SARS coronavirus genome expression. J. Gen. Virol. (2003) 84(9):2305-2315.
25. GALLAGHER TM, BUCHMEIER MJ: Coronavirus spike proteins in viral entry and pathogenesis. Virology (2001) 279(2):371-374.
26. VENNEMA H, HEIJNEN L, ZIJDERVELD A et al.: Intracellular transport of recombinant coronavirus spike proteins: implications for virus assembly. J. Virol. (1990) 64(1):339-346.
27. DVEKSLER GS, PENSIERO MN, CARDELLICHIO CB et al.: Cloning of the mouse hepatitis virus (MHV) receptor: Expression in human and hamster cell lines confers susceptibility to MHV. J. Virol. (1991) 65(12):6881-6891.
28. WILLIAMS RK, JIANG GS, HOLMES KV: Receptor for mouse hepatitis virus is a member of the carcinoembryonic antigen family of glycoproteins. Proc. Natl. Acad. Sci. USA (1991) 88(13):5533-5536.
29. DELMAS B, GELFI J, L'HARIDON R et al.: Aminopeptidase N is a major receptor for the entero-pathogenic coronavirus TGEV. Nature (1992) 357(6377):417-420.
30. YEAGER CL, ASHMUN RA, WILLIAMS RK et al.: Human aminopeptidase N is a receptor for human coronavirus 229E. Nature (1992) 357(6377):420-422.
31. BENBACER L, KUT E, BESNARDEAU L, LAUDE H, DELMAS B: Interspecies aminopeptidase-N chimeras reveal species-specific receptor recognition by canine coronavirus, feline infectious peritonitis virus, and transmissible gastroenteritis virus. J. Virol. (1997) 71(1):734-737.
32. LI W, MOORE MJ, VASILIEVA N et al.: Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature (2003) 426(6965):450-454.
33. VENNEMA H, GODEKE GJ, ROSSEN JW et al.: Nucleocapsid-independent assembly of coronavirus-like particles by co-expression of viral envelope protein genes. EMBO J. (1996) 15(8):2020-2028.
34. RISCO C, ANTON IM, ENJUANES L, CARRASCOSA JL: The transmissible gastroenteritis coronavirus contains a spherical core shell consisting of M and N proteins. J. Virol. (1996) 70(7):4773-4777.
35. TOOZE J, TOOZE SA, FULLER SD: Sorting of progeny coronavirus from condensed secretory proteins at the exit from the trans-Golgi network of AtT20 cells. J. Cell Biol. (1987) 105(3):1215-1226.
36. BOS EC, LUYTJES W, VAN DER MEULEN H, KOERTEN HK, SPAAN WJ: The production of recombinant infectious DI-particles of a murine coronavirus in the absence of helper virus. Virology (1996) 218(1):52-60.
37. CORSE E, MACHAMER CE: The cytoplasmic tails of infectious bronchitis virus E and M proteins mediate their interaction. Virology (2003) 312(1):25-34.
38. STURMAN LS, HOLMES KV, BEHNKE J: Isolation of coronavirus envelope glycoproteins and interaction with the viral nucleocapsid. J. Virol. (1980) 33(1):449-462.
39. COMPTON SR, ROGERS DB, HOLMES KV, FERTSCH D, REMENICK J, McGOWAN JJ: In vitro replication of mouse hepatitis virus strain A59. J. Virol. (1987) 61(6):1814-1820.
40. BARBER GN: Host defense, viruses and apoptosis. Cell Death Differ. (2001) 8(2):113-126.
41. SEN GC: Viruses and interferons. Ann. Rev. Microbiol. (2001) 55:255-281.
42. LINDBO JA, SILVA-ROSALES L, PROEBSTING WM, DOUGHERTY WG: Induction of a highly specific antiviral state in transgenic plants-implications for regulation of gene expression and virus resistance. Plant Cell (1993) 5(12):1749-1759.
43. VOINNET O, PINTO YM, BAULCOMBE DC: Suppression of gene silencing: a general strategy used by diverse DNA and RNA viruses of plants. Proc. Natl. Acad. Sci. USA (1999) 96(24):14147-4152.
44. VANCE V, VAUCHERET H: RNA silencing in plants-defense and counterdefense. Science (2001) 292(5525):2277-2280.
45. MONTGOMERY MK, XU S, FIRE A: RNA as a target of double-stranded RNA-mediated genetic interference in Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA (1998) 95(26):15502-15507.
46. NISHIKURA K: A short primer on RNAi: RNA-directed RNA polymerase acts as a key catalyst. Cell (2001) 107(4):415-418.
47. SHARP PA: RNA interference - 2001. Genes Dev. (2001) 15(5):485-490.
48. TIJSTERMAN M, KETTING RF, PLASTERK RH: The genetics of RNA silencing. Ann. Rev. Genet. (2002) 36:489-519.
49. JORGENSEN R: Altered gene expression in plants due to trans interactions between homologous genes. Trends Biotech. (1990) 8(12):340-344.
50. ROMANO N, MACINO G: Quelling: transient inactivation of gene expression in Neurospora crassa by transformation with homologous sequences. Mol. Microbiol. (1992) 6(22):3343-3353.
51. FIRE A, XU S, MONTGOMERY MK, KOSTAS SA, DRIVER SE, MELLO CC: Potent and specific genetics interference by double-stranded RNA in Caenorhabitis elegans. Nature (1998) 391(6669):806-811.
52. CAPLEN NJ, PARRISH S, IMANI F, FIRE A, MORGAN RA: Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl Acad. Sci. USA (2001) 98(17):9742-9747.
53. ELBASHIR SM, HARBORTH J, LENDECKEL W, YALCIN A, WEBER K, TUSCHL T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 411(6836):494-498.
54. STARK GR, KERR IM, WILLIAMS BR, SILVERMAN RH, SCHREIBER RD: How cells respond to interferons. Ann. Rev. Biochem. (1998) 67:227-264.
55. SEMIZAROV D, FROST L, SARTHY A et al.: Specificity of short interfering RNA determined through gene expression signatures. Proc. Natl. Acad. Sci. USA (2003) 100(11):6347-6352.
56. LICHNER Z, SILHAVY D, BURGYAN J: Double-stranded RNA-binding proteins proteins could suppress RNA interference-mediated antiviral defences. J. Gen. Virol. (2003) 84(4):975-80.
57. SALEH MC, VAN RIJ RP, ANDINO R: RNA silencing in viral infections: insights from poliovirus. Virus Res. (2004) 102(1):11-17.
58. TAN FL, YIN JQ: RNAi, a new therapeutic strategy against viral infection. Cell Res. (2004) 14(6):460-466.
59. STEVENSON M: Therapeutic potential of RNA interference. N. Engl. J. Med., (2004) 351(17):1772-1777.
60. YIN JQ, WAN Y: RNA-mediated gene regulation system: now and the future. Int. J. Mol. Med. (2002) 10(4):355-365.
61. HUTVAGNER G, ZAMORE PD: RNAi: nature abhors a double-strand. Curr. Opin. Genet. Dev. (2002) 12(2):225-232.
62. BERNSTEIN E, CAUDY AA, HAMMOND SM, HANNON GJ: Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature (2001) 409(6818):363-366.
63. ELBASHIR SM, LENDECKEL W, TUSCHL T: RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. (2001) 15(2):188-200.
64. HAMMOND SM, BOETTCHER S, CAUDY AA, KOBAYASHI R, HANNON GJ: Argonaute2, a link between genetic and biochemical analyses of RNAi. Science (2001) 293(5532):1146-1150.
65. MARTINEZ J, PATKANIOWSKA A, URLAUB H, LUHRMANN R, TUSCHL T: Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell (2002) 110(5):563-574.
66. DOUGHERTY W, PARKS T: Transgenes and gene suppression: telling us something new? Curr. Opin. Cell Biol. (1995) 7(3):399-405.
67. HOLEN T, AMARZGUIOUI M, WIIGER MT, BABAIE E, PRYDZ H: Positional effects of short interfering RNAs targeting the human coagulation trigger tissue factor. Nucleic Acids Res. (2002) 30(8):1757-1766.
68. MIYAGISHI M, SUMIMOTO H, MIYOSHI H, KAWAKAMI Y, TAIRA K: Optimization of an siRNA-expression system with an improved hairpin and its significant suppressive effects in mammalian cells. J Gene Med. (2004) 6(7):715-723.
69. HAMADA M, OHTSUKA T, KAWAIDA R et al.: Effects on RNA interference in gene expression (RNAi) in cultured mammalian cells of mismatches and the introduction of chemical modifications at the 3′-ends of siRNAs. Antisense Nucleic Acid Drug Dev. (2002) 12(5):301-309.
70. SCHWARZ DS, HUTVAGNER G, DU T, XU Z, ARONIN N, ZAMORE PD: Asymmetry in the assembly of the RNAi enzyme complex. Cell (2003) 115(2):199-208.
71. KHVOROVA A, REYNOLDS A, JAYASENA SD: Functional siRNAs and miRNAs exhibit strand bias. Cell (2003) 11(2):209-216.
72. UI-TEI K, NAITO Y, TAKAHASHI F et al.: Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res. (2004) 32(3):936-948.
73. CASTANOTTO D, ROSSI JJ: Construction and transfection of PCR products expressing siRNAs or shRNAs in mammalian cells. Methods Mol. Biol. (2004) 252:509-514.
74. YANG D, BUCHHOLZ F, HUANG Z et al.: Short RNA duplexes produced by hydrolysis with Escherichia coli RNase III mediate effective RNA interference in mammalian cells. Proc. Natl. Acad. Sci. USA (2002) 99(15):9942-9947.
75. MILLIGAN JF, GROEBE DR, WITHERELL GW, UHLENBECK OC: Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates. Nucleic Acids Res. (1987) 15(21):8783-8798.
76. GITLIN L, KARELSKY S, ANDINO R: Short interfering RNA confers intracellular antiviral immunity in human cells. Nature (2002) 418(6896):430-434.
77. RUBINSON DA, DILLON CP, KWIATKOWSKI AV et al.: A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat. Genet. (2003) 33(3):401-406.
78. ZHAO LJ, JIAN H, ZHU H: Specific gene inhibition by adenovirus mediated expression of small interfering RNA. Gene (2003) 316:137-141.
79. HAN S, MAHATO RI, SUNG YK, KIM SW: Development of biomaterials for gene therapy. Mol. Ther. (2000) 2(4):302-317.
80. COLBERE-GARAPIN F, BLONDEL B, SAULNIER A, PELLETIER I, LABADIE K: Silencing viruses by RNA interference. Microbes Infect. (2005) 7(4):767-775.
81. HE ML, ZHENG B, PENG Y et al.: Inhibition of SARS-associated coronavirus infection and replication by RNA interference. J. Am. Med. Assoc. (2003) 290(20):2665-2666.
82. WANG Z, REN L, ZHAO X et al.: Inhibition of severe acute respiratory syndrome virus replication by small interfering RNAs in mammalian cells. J. Virol. (2004) 78(14):7523-7527.
83. ZHANG R, GUO Z, LU J et al.: Inhibiting severe acute respiratory syndrome-associated coronavirus by small interfering RNA. Chin. Med. J. (2003) 116(8):1262-1264.
84. ZHANG Y, LI T, FU L et al.: Silencing SARS-CoV Spike protein expression in cultured cells by RNA interference. FEBS Lett. (2004) 560(1-3):141-146.
85. LI T, ZHANG Y, FU L et al.: siRNA targeting the leader sequence of SARS-CoV inhibits virus replication. Gene Ther. (2005) 12(9):751-761.
86. ZHENG BJ, GUAN Y, HEZ ML et al.: Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus. Antivir. Ther. (2005) 10(3):393-403.
87. WU CJ, HUANG HW, LIU CY, HONG CF, CHAN YL: Inhibition of SARS-CoV replication by siRNA. Antiviral Res. (2005) 65(1):45-48.
88. GE Q, FILIP L, BAI A, NGUYEN T, EISEN HN, CHEN J: Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc. Natl. Acad. Sci. USA (2004) 101(23):8676-8781.
89. TOMPKINS SM, LO CY, TUMPEY TM, EPSTEIN SL: Protection against lethal influenza virus challenge by RNA interference in vivo. Proc. Natl. Acad. Sci. USA. (2004) 101(23):8682-8686.
90. BITKO V, MUSIYENKO A, SHULYAYEVA O, BARIK S: Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. (2005) 11(1):50-55.
91. ZHANG W, YANG H, KONG X et al.: Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat. Med. (2005) 11(1):56-62.
92. LI BJ, TANG Q, CHENG D et al.: Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in rhesus macaque. Nat. Med. (2005) 11(9):944-951.
93. QIN C, WANG J, WEI Q et al.: An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus. J. Pathol. (2005) 206(3):251-259.